Phaseline

Targets › GJB2

GJB2 (Gap junction beta-2 protein): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 1; Other; next expected readout Dec 2027.

Structural component of gap junctions. Gap junctions are dodecameric channels that connect the cytoplasm of adjoining cells. (UniProt, P29033)

Open in Phaseline: the race on GJB2, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Skylark BioSKY-GJB2
Gene therapy replacing GJB2 (Connexin 26)
GJB2Phase 1GJB2-mediated Hearing LossDec 2027

Conditions

GJB2-mediated Hearing Loss (1)

Modalities

–

Companies

Skylark Bio (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.